While oils have always been the most common format, and continue to be, topicals appear to be growing in the US market, as have other categories such as flowers and vape. In addition, some of the top brands have also started to sell other types of cannabinoids aside from CBD, including CBG and CBN. This report provides a detailed analysis of the US market and the changes in product offerings and pricing between the first and third quarter of 2020.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyIf you are interested in the US market then this is the report for you. As well as gaining valuable data around brand engagement with product categories, and added and discontinued products, you’ll also find new product and price reduction analysis and information about new cannabinoids.
Table of contents1 Executive summary
2 Introduction
3 Brands and categories
4 Product analysis
5 Pricing analysis
6 Additional cannabinoid analysis
MethodologyUsing in-house data on the most common brands in both the online and offline markets, 66 unique brands were identified as the most representative in the US market. Together, they form the sample used to analyse the offerings and pricing of CBD products throughout the US. Where available from brand sources, product offerings were collected along with their RRPs. Where data was not available from brand sources, data from e-commerce websites was collected.
Latest reportsWhile oils have always been the most common format, and continue to be, topicals appear to be growing in the US market, as have other categories such as flowers and vape. In addition, some of the top brands have also started to sell other types of cannabinoids aside from CBD, including CBG and CBN. This report provides a detailed analysis of the US market and the changes in product offerings and pricing between the first and third quarter of 2020.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.